Success Metrics

Clinical Success Rate
92.3%

Based on 12 completed trials

Completion Rate
92%(12/13)
Active Trials
1(7%)
Results Posted
42%(5 trials)
Terminated
1(7%)

Phase Distribution

Ph phase_3
1
7%
Ph phase_4
2
13%
Ph not_applicable
1
7%
Ph phase_2
1
7%
Ph early_phase_1
2
13%
Ph phase_1
8
53%

Phase Distribution

10

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution15 total trials
Early Phase 1First-in-human
2(13.3%)
Phase 1Safety & dosage
8(53.3%)
Phase 2Efficacy & side effects
1(6.7%)
Phase 3Large-scale testing
1(6.7%)
Phase 4Post-market surveillance
2(13.3%)
N/ANon-phased studies
1(6.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

92.3%

12 of 13 finished

Non-Completion Rate

7.7%

1 ended early

Currently Active

1

trials recruiting

Total Trials

15

all time

Status Distribution
Active(1)
Completed(12)
Terminated(1)
Other(1)

Detailed Status

Completed12
Active, not recruiting1
unknown1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
15
Active
1
Success Rate
92.3%
Most Advanced
Phase 4

Trials by Phase

Early Phase 12 (13.3%)
Phase 18 (53.3%)
Phase 21 (6.7%)
Phase 31 (6.7%)
Phase 42 (13.3%)
N/A1 (6.7%)

Trials by Status

completed1280%
active_not_recruiting17%
unknown17%
terminated17%

Recent Activity

1 active trials
Showing 5 of 15
active_not_recruitingphase_1

Treatment of Orthostatic Intolerance

NCT00262470
completedphase_1

A Safety, Tolerability, and Pharmacokinetic Study of ND0612 Delivered as a Continuous Subcutaneous in Parkinson's Disease Patients

NCT02096601
completedphase_2

An Extension Study of Entacapone in Patients With Parkinson's Disease With End-of-dose Wearing-off. This Study is Not Recruiting in the United States

NCT00237263
completedearly_phase_1

Entacapone Combination With Imatinib for Treatment of GIST

NCT04006769
completedearly_phase_1

Pilot Study of Entacapone for Methamphetamine Abuse

NCT02058966
View all 15 trials

Clinical Trials (15)

Showing 15 of 15 trials
NCT00262470Phase 1

Treatment of Orthostatic Intolerance

Active Not Recruiting
NCT02096601Phase 1

A Safety, Tolerability, and Pharmacokinetic Study of ND0612 Delivered as a Continuous Subcutaneous in Parkinson's Disease Patients

Completed
NCT00237263Phase 2

An Extension Study of Entacapone in Patients With Parkinson's Disease With End-of-dose Wearing-off. This Study is Not Recruiting in the United States

Completed
NCT04006769Early Phase 1

Entacapone Combination With Imatinib for Treatment of GIST

Completed
NCT02058966Early Phase 1

Pilot Study of Entacapone for Methamphetamine Abuse

Completed
NCT02170376Phase 1

The Effect of BIA 9-1067 at Steady-state on the Levodopa Pharmacokinetics

Completed
NCT01568073Phase 3

Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With "Wearing-off" Phenomenon

Completed
NCT01519284Phase 1

Study of BIA 9-1067 to Investigate Its Effect on Levodopa Pharmacokinetic

Completed
NCT01840423Phase 1

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ODM-104 in Healthy Volunteers

Completed
NCT02349243Phase 1

Effect of Entacapone on Bodyweight Loss in Obese Population

Unknown
NCT01688089Phase 1

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ODM-103 in Healthy Volunteers

Completed
NCT00547911Phase 1

Augmenting Effects of L-DOPS With Carbidopa and Entacapone

Terminated
NCT00192855Not Applicable

Entacapone Augmentation for Schizophrenia

Completed
NCT00373087Phase 4

COMT Polymorphism and Entacapone Efficacy

Completed
NCT00906828Phase 4

Pharmacokinetics of Levodopa/Carbidopa Infusion With and Without Oral Catechol-O-methyl Transferase (COMT) Inhibitors

Completed

All 15 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
15